Vigabatrin

被引：37

作者：

French, JA ^{[1
]}

机构：

[1] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA

来源：

EPILEPSIA | 1999年 / 40卷

关键词：

vigabatrin; antiepileptic drug; seizures; epilepsy; GABA;

D O I：

10.1111/j.1528-1157.1999.tb00914.x

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Vigabatrin (VGB) is a structural analogue of the inhibitory neurotransmitter gamma-amino butyric acid (GABA), which produces its antiepileptic effect by irreversibly inhibiting the degradative enzyme GABA-transaminase. This produces an increase in central nervous system (CNS) GABA levels. VGB is among the few antiepileptic drugs (AEDs) that was synthesized sized with a specific targeted mechanism in mind and was subsequently demonstrated to function by that mechanism. Tiagabine, a GABA reuptake blocker, is the only other "designer drug" among the currently available AEDs. Therefore, VGB is among the few AEDs for which the mechanism of action is well understood. Recently, safety issues have been raised with regard to the use of vigabatrin. This article reviews the mechanism of action, pharmacokinetics, safety, and efficacy of VGB.

引用

页码：S11 / S16

页数：6

共 78 条

[1] NEUROPATHOLOGY OF A HUMAN HIPPOCAMPUS FOLLOWING LONG-TERM TREATMENT WITH VIGABATRIN - LACK OF MICROVACUOLES [J].

AGOSTI, R ;

YASARGIL, G ;

EGLI, M ;

WIESER, HG ;

WIESTLER, OD .

EPILEPSY RESEARCH, 1990, 6 (02) :166-170

[2] Vigabatrin as initial therapy for infantile spasms: A European retrospective survey [J].

Aicardi, J ;

Hauser, E ;

Steinbock, H ;

Szyper, M ;

Holsteen, V ;

Ostergaard, J ;

Pedersen, SA ;

Taudorf, K ;

BarthezCarpentier, MA ;

BadinandHubert, N ;

Berquin, P ;

Boulloche, J ;

Bourgeois, M ;

Carriere, JP ;

Chabrol, B ;

Chiron, C ;

Claris, O ;

Echenne, B ;

GauthierMorel, D ;

Livet, MO ;

Lopez, N ;

Mancini, J ;

Netter, JC ;

Quillerou, D ;

Richelme, CH ;

Rousselle, C ;

DeStMartin, A ;

DeSwarte, M ;

Auerswald, G ;

Brandl, U ;

Kurlemann, G ;

Siemes, H ;

Spohr, HL ;

Aarts, WFM ;

Begeer, JH ;

Heersma, DJ ;

Laan, LAEM ;

Peters, ACB ;

Cavazzutti, GB ;

Curatolo, P ;

Fois, A ;

Franzoni, E ;

Gobbi, G ;

Incorpora, G ;

Vigevano, F ;

Campistol, J ;

Campos, J ;

Casas, C ;

Herranz, JL ;

Nieto, M .

EPILEPSIA, 1996, 37 (07) :638-642

[3]

[Anonymous], 1991, The psychoses of epilepsy

[4]

AREZZO JC, 1989, BR J CLIN PHARM S1, V27, P53

[5] A double-blind, placebo-controlled study on the effect of vigabatrin on in vivo parameters of hepatic microsomal enzyme induction and on the kinetics of steroid oral contraceptives in healthy female volunteers [J].

Bartoli, A ;

Gatti, G ;

Cipolla, G ;

Barzaghi, N ;

Veliz, G ;

Fattore, C ;

Mumford, J ;

Perucca, E .

EPILEPSIA, 1997, 38 (06) :702-707

[6] THE EFFECT OF DIFFERENT VIGABATRIN TREATMENT REGIMENS ON CSF BIOCHEMISTRY AND SEIZURE CONTROL IN EPILEPTIC PATIENTS [J].

BENMENACHEM, E ;

PERSSON, LI ;

SCHECHTER, PJ ;

HAEGELE, KD ;

HUEBERT, N ;

HARDENBERG, J ;

DAHLGREN, L ;

MUMFORD, JP .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 :S79-S85

[7]

BENMENACHEM E, 1988, EPILEPSY RES, V2, P96

[8]

BENMENACHEM E, 1991, J CHILD NEUROL S2, V6, P11

[9] VIGABATRIN AND PSYCHOSIS [J].

BRODIE, MJ ;

MCKEE, PJW .

LANCET, 1990, 335 (8700) :1279-1279

[10] MULTICENTER LONG-TERM SAFETY AND EFFICACY STUDY OF VIGABATRIN FOR REFRACTORY COMPLEX PARTIAL SEIZURES - AN UPDATE [J].

BROWNE, TR ;

MATTSON, RH ;

PENRY, JK ;

SMITH, DB ;

TREIMAN, DM ;

WILDER, BJ ;

BENMENACHEM, E ;

MCBRIDE, RG ;

SHERRY, KM .

NEUROLOGY, 1991, 41 (03) :363-364

← 1 2 3 4 5 6 7 8 →